Company intelligence / Profile preview

Synvect

San Diego, California, USAsynvect.com ↗

Ownership: Private
Development stage: Commercial

Overview

Synvect has developed CRISPR-based technology to produce sterile male mosquitoes that mate with wild females, preventing reproduction and suppressing mosquito populations. Their first product, SEPARATOR, has received EPA approval and is being deployed in pilot programs across high-risk regions in the US.

Therapeutic areas: Infectious Diseases
Modalities: CRISPR-based gene knockouts
Industry: Non-Drug Biotech

Drug pipeline

1 asset

SEPARATOR

Commercial

Indications: Mosquito control

Partnerships

Government and mosquito control agencies in Florida, Texas, California

Beyond the preview

Go deeper on Synvect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synvect.

Explore the full profile